[1]白 雪,朱海波,邓 琦,等.PD-L1在急性髓系白血病中的表达及临床意义[J].医学信息,2019,32(06):79-81.[doi:10.3969/j.issn.1006-1959.2019.06.025]
　BAI Xue,ZHU Hai-bo,DENG Qi,et al.Expression and Clinical Significance of PD-L1 in Acute Myeloid Leukemia[J].Journal of Medical Information,2019,32(06):79-81.[doi:10.3969/j.issn.1006-1959.2019.06.025]
点击复制

PD-L1在急性髓系白血病中的表达及临床意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年06期
页码:
79-81
栏目:
论著
出版日期:
2019-03-15

文章信息/Info

Title:
Expression and Clinical Significance of PD-L1 in Acute Myeloid Leukemia
文章编号:
1006-1959（2019）06-0079-03
作者:
白 雪; 朱海波; 邓 琦; 李玉明
（天津市第一中心医院血液科，天津 300192）
Author(s):
BAI Xue; ZHU Hai-bo; DENG Qi; LI Yu-ming
(Department of Hematology,Tianjin First Central Hospital,Tianjin 300192,China)
关键词:
PD-L1; 急性髓系白血病; 免疫
Keywords:
PD-L1; Acute myeloid leukemia; Immunity
分类号:
R733.71
DOI:
10.3969/j.issn.1006-1959.2019.06.025
文献标志码:
A
摘要:
目的 探究程序性死亡分子1配体-1（PD-L1）在急性髓系白血病（AML）中的表达作用和临床意义。方法 选取2013年1月~2016年12月在我院进行治疗并确诊为AML的初治患者49例为观察组，选择同期在我院接受治疗的27例非恶性疾病如缺铁性贫血、巨幼细胞性贫血者作为对照组。对比两组患者血液中的PD-L1表达水平，分析患者性别、年龄、初诊白细胞计数、亚型的对血液中PD-L1的影响，确定PD-L1表达与临床疗效的相关性。结果 对照组患者治疗前的PD-L1表达与观察组比较，差异无统计学意义（P＞0.05）。治疗后，观察组的PD-L1表达高于对照组，统计学意义显著（P＜0.01）。单因素结果显示，PD-L1在AML初诊患者中的表达水平与患者的性别、年龄、初诊WBC数、分型无相关性（P＞0.05）；未缓解AML患者组PD-L1表达水平高于持续完全缓解组AML患者（P＜0.01）。结论 PD-L1可能参与AML的免疫逃逸机制，并可能与病情进展及治疗效果相关。
Abstract:
Objective To investigate the expression and clinical significance of programmed death molecule 1 ligand-1 (PD-L1) in acute myeloid leukemia (AML). Methods From January 2013 to December 2016, 49 patients with initial diagnosis of AML were enrolled in our hospital. The observation group was selected from 27 non-malignant diseases such as iron deficiency anemia and giants treated in our hospital. A young cell anemia was used as a control group. The levels of PD-L1 in the blood of the two groups were compared. The effects of gender, age, white blood cell count, and subtype on PD-L1 in the blood were analyzed to determine the correlation between PD-L1 expression and clinical efficacy. Results There was no significant difference in the expression of PD-L1 between the control group and the observation group (P>0.05). After treatment, the expression of PD-L1 in the observation group was higher than that in the control group,the statistical significance was significant (P<0.01). Univariate results showed that the expression level of PD-L1 in newly diagnosed patients with AML was not correlated with gender, age, number of newly diagnosed WBC, and type (P>0.05). The expression of PD-L1 was higher in patients without AML. Patients with AML were continuously relieved (P<0.01). Conclusion PD-L1 may be involved in the immune escape mechanism of AML and may be related to the progression of the disease and the therapeutic effect.

参考文献/References:

[1]王文超,汪宇,施乐华,等.PD-1/PD-L1信号通路及其在肿瘤免疫治疗中的作用[J].第二军医大学学报,2017,38(9):1190-1195. [2]徐凡,蔡真.PD-1/PD-L1抑制剂治疗急性髓细胞性白血病的研究进展[J].中国肿瘤生物治疗杂志,2018,25(6):634-639. [3]Xu F,Xu L,Wang Q,et al.Clinicopathological and prognostic value of programmed death ligand-1(PD-L1) in renal cell carcinoma: a meta -analysis[J].Int J Clin Exp Med,2015,8(9):14595-14603. [4]Mazel M,Jacot W,Pantel K,et al.Frequent expression of PD-L1 on circulating breast cancer cells[J].Mol Oncol,2015,9(9):1773-1782. [5]陈泽,蔡志梅,赵利东,等.BCL-2与PD-L1联合检测在预测初治急性白血病预后中的价值分析[J].中国实验血液学杂志,2017,25(6):1636-1640. [6]Zheng ZX,Bu ZD,Liu XJ,et al.Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications[J].Chin J Cancer Res,2014,26(1):104-111. [7]李萌,董航,赵悦荣,等.sTRAIL及sPD-L1在急性髓细胞白血病患者血清中的表达[J].黑龙江医药科学,2018,41(1):63-65. [8]李金花,庞楠楠,张正昊,等.PD-1/PD-L1共刺激分子在慢性淋巴细胞白血病患者中的表达及临床意义[J].中华血液学杂志,2017,38(3):198. [9]Wang X,Li J,Dong K,et al.Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia[J].Cell Signal,2015,27(3):443-452. [10]马红,李宁.PD-L1的表达与初发急性白血病患者临床特征及预后关系的研究[J].中国实验血液学杂志,2016,24(4):1034-1038. [11]Madorsky Rowdo FP,Baron A,Urrutia M,et al.Immunotherapy in cancer:a combat between tumors and the immune system;you win some, you lose some[J].Front Immunol,2015,26(6):127. [12]张占芳,张秋堂,邢海洲,等.PD-L1在急性白血病中的表达及其临床意义[J].中国实验血液学杂志,2015,23(4):930-934. [13]Giri A,Walia SS,Gajra A.Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer[J].Rev Recent Clin Trials,2016,11(4):297-305. [14]de Guillebon E,Roussille P,Frouin E.Anti program death-1/anti program death-ligand 1 in digestive cancers[J].World J Gastrointest Oncol,2015,7(8):95-101.

相似文献/References:

[1]杨 静,王 新.PD-L1、MMP-9、IMP3表达水平与乳腺癌病理分期、组织学分级及预后的关系研究[J].医学信息,2022,35(14):53.[doi:10.3969/j.issn.1006-1959.2022.14.011]
　YANG Jing,WANG Xin.The Relationship Between PD-L1,MMP-9,IMP3 Expression Levels and Pathological Staging,Histological Grade and Prognosis of Breast Cancer[J].Journal of Medical Information,2022,35(06):53.[doi:10.3969/j.issn.1006-1959.2022.14.011]
[2]曹忠钰,白家英,李 泽.以面瘫为首发症状的小儿急性髓系白血病1例并文献复习[J].医学信息,2020,33(03):190.[doi:10.3969/j.issn.1006-1959.2019.17.065]
[3]曾雪娇,谢仁古丽·阿力木,庞楠楠,等.急性白血病预后相关基因突变的研究[J].医学信息,2021,34(20):41.[doi:10.3969/j.issn.1006-1959.2021.20.010]
　ZENG Xue-jiao,XIERENGULI Alimu,PANG Nan-nan,et al.Research on Prognosis-related Gene Mutations of Acute Leukemia[J].Journal of Medical Information,2021,34(06):41.[doi:10.3969/j.issn.1006-1959.2021.20.010]
[4]赵崇山,王宁方.脾脏硬度联合流式细胞术在急性髓系白血病微小残留病监测中的意义[J].医学信息,2022,35(05):121.[doi:10.3969/j.issn.1006-1959.2022.05.031]
　ZHAO Chong-shan,WANG Ning-fang.The Significance of Spleen Stiffness Measurement Combine with Flow Cytometry in Acute Myeloid Leukemia Minimal Residual Disease[J].Journal of Medical Information,2022,35(06):121.[doi:10.3969/j.issn.1006-1959.2022.05.031]
[5]张献方,孟凡亮.CD47蛋白的表达与非小细胞肺癌预后的相关性研究[J].医学信息,2023,36(12):96.[doi:10.3969/j.issn.1006-1959.2023.12.018]
　ZHANG Xian-fang,MENG Fan-liang.Correlation Between the Expression of CD47 Protein and the Prognosis of Non-small Cell Lung Cancer[J].Journal of Medical Information,2023,36(06):96.[doi:10.3969/j.issn.1006-1959.2023.12.018]

更新日期/Last Update: 2019-03-15